


PHARMACEUTICAL 2020

Larimar Therapeutics Inc. Rank 212 of 362





PHARMACEUTICAL 2020

Larimar Therapeutics Inc. Rank 212 of 362

The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 150% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is -232%, being 71% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	71,503
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,190
Liabilities, Non-Current	6,456
Other Assets	8,410
Other Compr. Net Income	68
Other Expenses	5,553
Other Liabilities	8,464
Other Net Income	248
Property and Equipment	821
Research and Development	23,886
Revenues	0
Selling, General and Administrative Expense	16,215

Output Variable	Value in 1000 USD
Assets	80,734
Liabilities	27,110
Expenses	45,654
Stockholders Equity	53,624
Net Income	-45,406
Comprehensive Net Income	-45,372
Economic Capital Ratio	-232%